Thiogenesis Therapeutics Corp Sustainability Reports
Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company that develops next-generation sulfur-based thiol prodrug therapies. Its primary focus is treating rare pediatric metabolic and inherited mitochondrial diseases, such as nephropathic cystinosis and Leigh syndrome.
Sector: Manufacturing
Country: Canada
Exchange: TSX Venture Exchange
LEI: 9845006CBA639FFD6454
FIGI: BBG00NSLMCF5
1 reports from 2024 to 2024